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A bs tr ac t
Background
It is not known whether drugs that block the renin–angiotensin system reduce the risk 
of diabetes and cardiovascular events in patients with impaired glucose tolerance.
Methods
In this double-blind, randomized clinical trial with a 2-by-2 factorial design, we 
assigned 9306 patients with impaired glucose tolerance and established cardiovas-
cular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) 
or placebo (and nateglinide or placebo) in addition to lifestyle modification. We then 
followed the patients for a median of 5.0 years for the development of diabetes (6.5 
years for vital status). We studied the effects of valsartan on the occurrence of three 
coprimary outcomes: the development of diabetes; an extended composite outcome 
of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, 
hospitalization for heart failure, arterial revascularization, or hospitalization for 
unstable angina; and a core composite outcome that excluded unstable angina and 
revascularization.
Results
The cumulative incidence of diabetes was 33.1% in the valsartan group, as com-
pared with 36.8% in the placebo group (hazard ratio in the valsartan group, 0.86; 
95% confidence interval [CI], 0.80 to 0.92; P<0.001). Valsartan, as compared with 
placebo, did not significantly reduce the incidence of either the extended cardiovas-
cular outcome (14.5% vs. 14.8%; hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P = 0.43) 
or the core cardiovascular outcome (8.1% vs. 8.1%; hazard ratio, 0.99; 95% CI, 0.86 
to 1.14; P = 0.85).
Conclusions
Among patients with impaired glucose tolerance and cardiovascular disease or risk 
factors, the use of valsartan for 5 years, along with lifestyle modification, led to a 
relative reduction of 14% in the incidence of diabetes but did not reduce the rate of 
cardiovascular events. (ClinicalTrials.gov number, NCT00097786.)
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Patients with impaired glucose tol-erance have an increased risk of type 2 dia-betes mellitus and cardiovascular disease.1-3 
Interventions that might reduce the incidence of 
diabetes and associated rates of death and com-
plications from cardiovascular causes in such pa-
tients are therefore of importance.3 Several trials 
have shown that lifestyle modification, including 
increased physical activity and weight loss, re-
duces the risk of diabetes, although these trials 
did not evaluate cardiovascular outcomes.3-8 Cer-
tain drugs, including metformin, acarbose, and 
rosiglitazone, also reduce the incidence of diabe-
tes, although their effect on cardiovascular events 
is uncertain.6,9,10
Another pharmacologic approach to reducing 
the risk of diabetes and cardiovascular disease is 
inhibition of the renin–angiotensin system. Some 
studies have shown that angiotensin-converting–
enzyme (ACE) inhibitors and angiotensin-receptor 
blockers (ARBs) may reduce the incidence of dia-
betes and the risk of cardiovascular events among 
patients with hypertension and other cardiovas-
cular diseases.11-14 In most of these studies, how-
ever, the incidence of diabetes was not the pri-
mary outcome of the trial, nor was it confirmed 
by systematic glucose measurement.15
A single trial, the Diabetes Reduction Assess-
ment with Ramipril and Rosiglitazone Medica-
tion (DREAM) study (ClinicalTrials.gov number, 
NCT00095654), attempted to prospectively and 
robustly ascertain the effect of an ACE inhibitor 
in a population at high risk for diabetes, although 
the study did not test this treatment in addition 
to lifestyle modification and was not powered to 
evaluate cardiovascular outcomes.16 Ramipril did 
not reduce the incidence of diabetes, although 
plasma glucose levels measured 2 hours after an 
oral glucose load were significantly lower in the 
ramipril group.16
We conducted a large, prospective trial, called 
Nateglinide and Valsartan in Impaired Glucose 
Tolerance Outcomes Research (NAVIGATOR), to 
evaluate whether nateglinide, a blood glucose–
lowering drug in the meglitinide class, or valsar-
tan, an ARB, would reduce the risk of diabetes and 
cardiovascular events among patients with im-
paired glucose tolerance and established cardio-
vascular disease or cardiovascular risk factors. 
This treatment was tested in addition to lifestyle 
modification.17 Here we report the results of the 
valsartan portion of the study; the results of the 
nateglinide portion are discussed elsewhere in this 
issue of the Journal.18
Me thods
Study Patients
From January 2002 through January 2004, we re-
cruited patients at 806 centers in 40 countries. All 
eligible patients had impaired glucose tolerance,3 
a fasting plasma glucose level of at least 95 mg per 
deciliter (5.3 mmol per liter) but less than 126 mg 
per deciliter (7.0 mmol per liter), and one or more 
cardiovascular risk factors (if 55 years of age or 
older) or known cardiovascular disease (if 50 years 
of age or older). A screening glucose-tolerance 
test was performed 2 hours after a 75-g oral glu-
cose load to determine study eligibility. Impaired 
glucose tolerance was defined as a post-load plas-
ma glucose level of at least 140 mg per deciliter 
(7.8 mmol per liter) but less than 200 mg per deci-
liter (11.1 mmol per liter).3 (For details, see Sec-
tion 2 in Supplementary Appendix 1, available with 
the full text of this article at NEJM.org.) 
Exclusion criteria were laboratory abnormali-
ties or conditions that could interfere with as-
sessment of the safety or efficacy of a study drug, 
the use of an ACE inhibitor or ARB for the treat-
ment of hypertension (although ACE inhibitors 
were allowed for other indications), and the use 
of an antidiabetic medication within the previous 
5 years.17
The trial was approved by each center’s ethics 
committee. All patients provided written informed 
consent.
Study Treatment
We used a computerized, interactive voice-response 
telephone randomization system involving con-
cealed study-group assignments to randomly as-
sign patients to valsartan or matching placebo (and 
nateglinide or matching placebo) in a 2-by-2 fac-
torial design. Randomization was stratified ac-
cording to center, with a block size of eight with-
in each center. Valsartan was started at a dose of 
80 mg once daily, with an increase after 2 weeks 
to 160 mg once daily; dose reduction or interrup-
tion because of adverse events or for other clini-
cal reasons was permitted.
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Lifestyle Modification
All patients were required to participate in a study-
specific lifestyle-intervention program that was 
designed to reduce the risk of diabetes. The ob-
jective of the intervention was to help patients 
achieve and maintain a 5% weight loss, reduce 
intake of saturated and total dietary fat, and in-
crease physical activity to 150 minutes weekly (see 
Section 3 in Supplementary Appendix 1). Site per-
sonnel were trained to administer this program 
and provided materials designed to facilitate adher-
ence at each clinic visit, with reinforcement and 
monitoring by telephone between study visits.
Study Procedures
After the dose-adjustment phase, patients were 
seen every 6 months. Fasting plasma glucose lev-
els were measured every 6 months for the first 
3 years and then annually. Oral glucose tolerance 
tests were performed yearly. The morning dose of 




Initially, there were two coprimary outcomes: the 
incidence of diabetes and an extended cardiovas-
cular outcome, a composite of death from cardio-
vascular causes, nonfatal myocardial infarction, 
nonfatal stroke, hospitalization for heart failure, 
arterial revascularization, or hospitalization for 
unstable angina. A third coprimary core cardio-
vascular outcome (a composite of death from car-
diovascular causes, nonfatal myocardial infarction, 
nonfatal stroke, and hospitalization for heart fail-
ure), which was initially a secondary composite 
outcome, was added, as described previously.17,19
Incidence of Diabetes
Diabetes was defined as a fasting plasma glucose 
level of 126 mg per deciliter (7.0 mmol per liter) 
or more or a plasma glucose level of 200 mg per 
deciliter (11.1 mmol per liter) or more as mea-
sured 2 hours after an oral glucose load,20,21 con-
firmed within 12 weeks by a glucose tolerance 
test. The date of onset of diabetes was defined as 
the date of the first diagnostic glucose value. An 
independent committee whose members were not 
aware of study-group assignments adjudicated the 
small number of cases in which patients received 
a diagnosis of diabetes or were started on an an-
tidiabetic drug without undergoing the study-
specified laboratory investigations.
Death, Hospitalization, and Other Cardiovascular 
Events
An independent committee whose members were 
unaware of study-group assignments adjudicated 
the occurrence of death, hospitalization, and po-
tential cardiovascular events that occurred in pa-
tients who were not hospitalized (for definitions 
of these events, see Section 4 in Supplementary Ap-
pendix 1). 
Study Oversight
The trial was sponsored by Novartis Pharma and 
was designed in collaboration with an academic 
executive committee and monitored by an inde-
pendent safety committee.17 Data were collected, 
managed, and analyzed by the sponsor, with over-
sight from the executive committee, and the analy-
ses were replicated by an independent academic 
statistician. The manuscript was prepared by a 
writing group, whose members had unrestricted 
access to the data, and was subsequently revised 
by all the authors. All authors decided to submit 
the manuscript for publication and assume re-
sponsibility for its accuracy and completeness. 
The trial protocol is available in Supplementary 
Appendix 2.
Statistical Analysis
On the assumption that the study would continue 
until the extended cardiovascular outcome oc-
curred in 1374 patients in the two study groups 
combined, we anticipated a power of 90% to de-
tect a 20% reduction in the hazard rate in the val-
sartan group, assuming subadditivity of the effects 
of valsartan and nateglinide and allowing for an 
annual discontinuation rate of 6.9%.17 These calcu-
lations were revised after an updated meta-analysis 
of trials of renin–angiotensin blockers suggesting 
that the reduction in the hazard of the extended 
cardiovascular outcome was more likely to be 12% 
(providing a power of 64%) and 18% for the core 
cardiovascular outcome (providing a power of 74%, 
assuming the occurrence of 784 core events); the 
estimated power to show a reduction in at least 
one of the cardiovascular outcomes was 77%.17,19
While accumulating 1374 extended cardiovas-
cular events, we anticipated that more than 3000 
patients would have progression to diabetes, en-
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suring a power of more than 99% to detect a haz-
ard reduction of 18%. Because we examined the 
effects of two drugs (valsartan and nateglinide) 
on three primary outcomes in a factorial manner, 
we adjusted for the three tests that were performed 
for each study drug (but not across drugs). Two-
sided P values are given, with protocol-specified 
one-sided values for the coprimary outcomes and 
their components. The one-sided familywise type I 
error rate of 2.5% for each drug was controlled 
with the use of a closed-testing procedure, with 
one fifth of the alpha assigned to diabetes and 
four fifths to the two cardiovascular outcomes, 
since more cases of incident diabetes than cardio-
vascular events were anticipated. This allowed for 
testing of each primary outcome even if the other 
two outcomes did not show a significant result. 
An O’Brien–Fleming–type alpha spending ap-
proach accounted for the interim efficacy analy-
sis performed with 30% of the target number of 
extended cardiovascular events (a one-sided alpha 
of 0.00004) in November 2005.22 (For details, see 
Section 5 in Supplementary Appendix 1.)
Log-rank tests that were stratified according 
to a history of cardiovascular disease and nateg-
linide treatment were used to compare the val-
sartan and placebo groups for the time to a first 
event in the extended or core composite outcome. 
Given the fixed-time schedule for glucose mea-
surement, a discrete time proportional-odds model 
was used for the incidence of diabetes. We also 
conducted predefined analyses of the components 
of the composite cardiovascular outcomes, time 
to death from any cause, time to cardiovascular-
related hospitalization, indexes of hyperglycemia, 
and body weight. The possibility of interaction 
between valsartan and nateglinide was tested for 
each outcome reported. The effects of study treat-
ment were evaluated in prespecified subgroups.17 
We compared baseline characteristics, safety, and 
other trial assessments using summary statistics.
R esult s
Study Patients
Of 43,502 patients who underwent screening, 
9518 were randomly assigned to treatment. After 
randomization, 212 patients were excluded from 
the analysis, since 10 sites were closed because of 
deficiencies in meeting Good Clinical Practice 
guidelines, which left 9306 patients who could be 
evaluated (Fig. 1).
Among patients who were taking a study drug 
at 6 months, 91.1% of those who were assigned 
to receive valsartan were taking the higher dose 
(160 mg daily); this proportion was 94.6% in the 
placebo group (P<0.001). At 1 year, 77.6% of pa-
tients in the valsartan group were taking a study 
drug, as compared with 79.2% of those in the 
placebo group (P = 0.06). The corresponding pro-
portions in the valsartan group and the placebo 
group were 72.3 and 73.3% at 3 years (P = 0.29) 
and 66.2% and 66.7% at 5 years (P = 0.59).
Baseline characteristics were similar in the val-
sartan and placebo groups. Of the 9306 patients 
who were evaluated, 2266 (24.3%) had known car-
diovascular disease, mainly coronary artery dis-
ease. Of the remainder who had cardiovascular 
risk factors only, 79.6% had a history of hyper-
tension.
Patients with cardiovascular disease were treat-
ed more intensively at baseline than were those 
who had risk factors only: 21.5% received an ACE 
inhibitor, as compared with 2.7% of those with 
risk factors only; 75.8% received antiplatelet treat-
ment, as compared with 24.2% of those with risk 
factors only; 61.7% received a beta-blocker, as 
compared with 32.2% of those with risk factors 
only; and 64.1% received lipid-modifying therapy, 
as compared with 30.2% of those with risk fac-
tors only.
The use of diuretics and calcium-channel block-
ers was similar in the two groups. The use of 
nonstudy cardiovascular treatments increased dur-
ing follow-up (Table 1).23,24 At the last study visit, 
20.4% of patients in the valsartan group and 24.0% 
of those in the placebo group were receiving an 
open-label renin–angiotensin inhibitor (P<0.001). 
In the placebo group, as compared with the val-
sartan group, 5.3% more patients were taking a 
diuretic, and 3.1% more were taking a beta-blocker 
(P<0.001 for both comparisons).
Blood-pressure levels decreased more in the 
valsartan group than in the placebo group, with 
a mean (±SD) overall reduction in systolic pres-
sure of 6.3±14.2 mm Hg in the valsartan group, 
as compared with a reduction of 3.8±13.8 mm Hg 
in the placebo group (between-group difference, 
2.8 mm Hg; 95% confidence interval [CI], 2.4 to 
3.2; P<0.001) with adjustment for region, cardio-
vascular history, and nateglinide treatment (Fig. 
2A). The mean reduction in diastolic pressure was 
4.4±8.4 mm Hg in the valsartan group, as com-
pared with a reduction of 3.0±8.1 mm Hg in the 
placebo group (difference, 1.4 mm Hg; 95% CI, 
1.2 to 1.7; P<0.001) (Fig. 2B). There was a small 
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decline in weight during follow-up that was slight-
ly less in the valsartan group (0.31±3.9 kg) than 
in the placebo group (0.60±4.0 kg), a difference 
of 0.28 kg (95% CI, 0.12 to 0.44; P<0.001) (Fig. 2C). 
There was little change in waist circumference 
during the study, with an increase of 0.08±6.5 cm 
in the valsartan group, as compared with a de-
crease of 0.16±6.5 cm in the placebo group (dif-
ference, 0.20 cm; 95% CI, −0.05 to 0.45; P = 0.12) 
(Fig. 2D).
Follow-up
Among surviving patients who had not withdrawn 
consent and had not received a clinical diagnosis of 
diabetes, 80% underwent measurement of fasting 
plasma glucose or plasma glucose 2 hours after an 
oral glucose load at the close-out visit or during the 
final 6 months of the study. The rate of loss to fol-
low-up (including withdrawal of consent) was 
12.7% in the valsartan group (588 patients) and 
13.3% in the placebo group (623 patients). Because 
many discontinuations occurred late in the study, 
information on vital status was available for 96% of 
possible follow-up time in the two study groups. 
The median follow-up was 6.5 years for vital status, 
6.4 years for the core cardiovascular outcome, 6.3 
years for the extended cardiovascular outcome, 
and 5.0 years for the incidence of diabetes.
6 col
33p9
9518 Were randomly assigned to receive either
valsartan or placebo
43,502 Patients with cardiovascular disease or 
cardiovascular risk factors were screened
39,282 (90.3%) Were screened once
4133 (9.5%) Were screened twice
87 (0.2%) Were screened three
or four times
33,984 Were excluded
24,023 Did not meet inclusion criteria
6719 Had an abnormal laboratory value
1652 Had an abnormal test result 
853 Withdrew consent
293 Had other reasons
215 Were ineligible owing to medical
history
171 Were taking excluded medication
58 Had intercurrent medical event
9306 Were included in the final analysis
212 Were excluded because of protocol
deficiencies at site
4631 Were assigned to receive valsartan
with or without nateglinide
4675 Were assigned to receive placebo
with or without nateglinide
883 Discontinued




468 Were lost to follow-up
327 Died
155 Withdrew participation
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Figure 1. Enrollment and Outcomes.
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(N = 4675) P Value
Age — yr 63.7±6.8 63.8±6.8 0.27
Female sex — no. (%) 2314 (50.0) 2397 (51.3) 0.29
Race — no. (%)†
White 3849 (83.1) 3885 (83.1) 0.96
Black 113 (2.4) 123 (2.6)
Asian 298 (6.4) 315 (6.7)
Other 371 (8.0) 352 (7.5)
Weight — kg 83.5±17.4 83.8±17.1 0.38
Body­mass index‡ 30.4±5.5 30.6±5.3 0.29
Waist circumference — cm
All patients 101±14 101±14 0.36
Men 104±13 104±12
Women 98±14 98±14
Sitting blood pressure — mm Hg
Systolic 139.4±17.8 139.9±17.1 0.21
Diastolic 82.5±10.4 82.6±10.1 0.93
Cardiovascular risk factors — no. (%)
Any 4565 (98.6) 4621 (98.8) 0.26
Family history of premature heart disease 782 (16.9) 762 (16.3) 0.44
Current smoker 518 (11.2) 507 (10.8) 0.59
Hypertension 3581 (77.3) 3635 (77.8) 0.62
Left ventricular hypertrophy 133 (2.9) 135 (2.9) 0.97
Microalbuminuria 61 (1.3) 53 (1.1) 0.42
Reduced HDL cholesterol 459 (9.9) 433 (9.3) 0.28
Elevated non­HDL cholesterol 2066 (44.6) 2097 (44.9) 0.82
History of cardiovascular disease — no. (%)
Any 1148 (24.8) 1118 (23.9) 0.30
Myocardial infarction 552 (11.9) 541 (11.6) 0.60
Angina or positive stress test 416 (9.0) 400 (8.6) 0.47
Percutaneous coronary intervention 190 (4.1) 172 (3.7) 0.29
Multivessel coronary­artery bypass grafting 182 (3.9) 198 (4.2) 0.46
Intermittent claudication 42 (0.9) 56 (1.2) 0.17
Peripheral­artery stenosis 32 (0.7) 22 (0.5) 0.16
Lower­limb angioplasty or bypass surgery 61 (1.3) 49 (1.0) 0.24
Nontraumatic leg or foot amputation 5 (0.1) 2 (<0.1) 0.25
Stroke of atherosclerotic origin 143 (3.1) 132 (2.8) 0.44
Family history of diabetes mellitus — no. (%) 1737 (37.5) 1810 (38.7) 0.25
Glycemic indexes
Fasting plasma glucose — mmol/liter 6.1±0.45 6.1±0.45 0.55
Plasma glucose 2 hr after glucose load — mmol/liter 9.2±0.93 9.2±0.94 0.44
Glycated hemoglobin — % 5.79±0.47 5.82±0.46 0.08
Metabolic syndrome — no. (%)§ 3825 (82.6) 3970 (85.0) 0.003
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(N = 4675) P Value
Lipids — mg/dl
Total cholesterol 210±42 210±42 0.78
HDL cholesterol 50±13 50±13 0.67
LDL cholesterol 126±37 127±37 0.99
Triglycerides 175±105 173±103 0.25
Median 151 150
Interquartile range 109–209 108–209
Creatinine — mg/dl 0.9±0.2 0.9±0.2 0.29
Estimated GFR¶
Mean — ml/min/1.73 m2 80.9±18.5 80.4±19.0 0.20
<60 ml/min/1.73 m2 — no. (%) 499 (10.8) 521 (11.1) 0.53
Ratio of urinary albumin (mg) to creatinine (g) 0.29
Median 7.1 7.1
Interquartile range 4.4–14.2 4.5–14.7
Concomitant medication — no. (%)‖
ACE inhibitor
Baseline 351 (7.6) 325 (7.0) 0.36
Last study visit 688 (14.9) 786 (16.8) 0.005
Angiotensin­receptor blocker
Baseline 18 (0.4) 29 (0.6) 0.12
Last study visit 275 (5.9) 353 (7.6) 0.002
Alpha­blocker
Baseline 289 (6.2) 288 (6.2) 0.87
Last study visit 213 (4.6) 260 (5.6) 0.04
Beta­blocker
Baseline 1863 (40.2) 1803 (38.6) 0.15
Last study visit 1840 (39.7) 2000 (42.8) <0.001
Calcium­channel blocker
Baseline 1483 (32.0) 1529 (32.7) 0.46
Last study visit 1537 (33.2) 1857 (39.7) <0.001
Diuretic
Baseline 1451 (31.3) 1509 (32.3) 0.36
Last study visit 1578 (34.1) 1841 (39.4) <0.001
Any antihypertensive drug
Baseline 3398 (73.4) 3418 (73.1) 0.90
Last study visit 3409 (73.6) 3696 (79.1) <0.001
Lipid­lowering drug**
Baseline 1782 (38.5) 1795 (38.4) 0.81
Last study visit 2298 (49.6) 2361 (50.5) 0.27
Aspirin or other antiplatelet drug
Baseline 1729 (37.3) 1696 (36.3) 0.50
Last study visit 2103 (45.4) 2130 (45.6) 0.64
Copyright © 2010 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org by JEAN-CHRISTOPHE PHILIPS on May 3, 2010 . 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 362;16 nejm.org april 22, 20101484
No interaction between valsartan and nateg li-
nide was observed for any of the outcomes de-
scribed (Section 6 in Supplementary Appendix 1).
Study Outcomes
Coprimary Diabetes Outcome
Diabetes mellitus developed in 1532 patients 
(33.1%) in the valsartan group and 1722 patients 
(36.8%) in the placebo group (Table 2 and Fig. 3). 
The hazard ratio for this outcome in the valsar-
tan group, as compared with the placebo group, 
was 0.86 (95% CI, 0.80 to 0.92; P<0.001 in both 
one-sided and two-sided tests). The effect of val-
sartan on progression to diabetes was consistent 
across all prespecified subgroups (Section 7A in 
Supplementary Appendix 1). The proportion of 
patients who were taking an antidiabetic medica-
tion at their last study visit was smaller in the 
valsartan group than in the placebo group 
(P<0.001) (Table 1).
Glycemia
During the study, the fasting plasma glucose level 
was reduced by a mean of 0.59 mg per deciliter 
(95% CI, 0.16 to 1.02) (0.03 mmol per liter [95% 
CI, 0.01 to 0.06]) in the valsartan group, as com-
pared with the placebo group (P<0.01) (Fig. 2E). 
The plasma glucose level 2 hours after a glucose 
load was reduced by a mean of 3.15 mg per deci-
liter (95% CI, 1.58 to 4.72) (0.17 mmol per liter 
[95% CI, 0.09 to 0.26]) in the valsartan group 
(P<0.001) (Fig. 2F).
Coprimary Cardiovascular Outcomes
The extended cardiovascular outcome occurred in 
672 patients (14.5%) in the valsartan group and 
693 patients (14.8%) in the placebo group (Table 2 
and Fig. 3). The hazard ratio for this outcome in 
the valsartan group, as compared with the placebo 
group, was 0.96 (95% CI, 0.86 to 1.07; P = 0.22 in 
a one-sided test; P = 0.43 in a two-sided test). The 
core cardiovascular outcome occurred in 375 pa-
tients (8.1%) in the valsartan group and 377 pa-
tients (8.1%) in the placebo group (hazard ratio, 
0.99; 95% CI, 0.86 to 1.14; P = 0.42 in a one-sided 
test; P = 0.85 in a two-sided test). The neutral ef-
fect of treatment was consistent for both outcomes 
across all prespecified subgroups (Sections 7B 
and 7C in Supplementary Appendix 1).
Exploratory Outcomes, Including Death
There was no significant difference between the 
study groups with respect to any of the compo-
nents of the extended cardiovascular outcome or 
the prespecified exploratory outcomes (Table 2). 
The numbers of deaths were 295 (6.4%) in the val-
sartan group and 327 (7.0%) in the placebo group 






(N = 4675) P Value
Antidiabetic drug
Baseline 1 (<0.1) 6 (0.1) 0.06
Last study visit 588 (12.7) 733 (15.7) <0.001
* Plus–minus values are means ±SD. Cochran–Mantel–Haenszel tests were used for categorical variables; F tests (vari­
ance ratio tests) were used for continuous variables. Both tests were stratified according to the use or nonuse of the 
other study drug (nateglinide) and presence or absence of a history of cardiovascular disease, except for cardiovascu­
lar disease or risk factors, which were stratified according to age (<55 years or ≥55 years). To convert the values for 
glucose to milligrams per deciliter, divide by 0.05551. To convert the values for cholesterol to millimoles per liter, mul­
tiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. To convert the val­
ues for creatinine to micromoles per liter, multiply by 88.4. ACE denotes angiotensin­converting enzyme, GFR glomer­
ular filtration rate, HDL high­density lipoprotein, and LDL low­density lipoprotein.
† Race was reported by investigators.
‡ The body­mass index (the weight in kilograms divided by the square of the height in meters) was adjusted for sex.
§ The metabolic syndrome was defined according to the guidelines of the International Diabetes Federation.23
¶ The estimated glomerular filtration rate was calculated with the use of the modified formula from the Modification of 
Diet in Renal Disease study for traceable serum creatinine values as measured by isotope­dilution mass spectrometry.24
‖ The last study visit was the last time point at which the investigator indicated whether the patient had been taking a 
concomitant medication. Such a visit was either the end­of­study visit or the last recorded visit before death or with­
drawal from the study.
** Statin use increased from 34 to 47% in the valsartan group and from 34 to 49% in the placebo group.
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Adverse Events and Discontinuation  
of Study Drug
Nasopharyngitis, back pain, and arthralgia were 
the most commonly reported individual adverse 
events (for a complete list, see Section 8 in Supple-
mentary Appendix 1). There was no excess of re-
nal dysfunction or hyperkalemia in the valsartan 
group, but hypotension-related adverse events were 
more common in the valsartan group (occurring 
in 42.4% of patients) than in the placebo group 
(35.9%) (P<0.001). During the course of the study, 
556 patients (12.0%) in the valsartan group and 
531 (11.4%) in the placebo group discontinued the 



























0 1 2 3 4 65
Years since Randomization
E Fasting Plasma Glucose
A Systolic Blood Pressure








AUTHOR, PLEASE NOTE: 
































0 1 2 3 4 65
Years since Randomization
B Diastolic Blood Pressure























0 1 2 3 4 65
Years since Randomization



















0 1 2 3 4 65
Years since Randomization




































0 1 2 3 4 65
Years since Randomization


























0 1 2 3 4 65
Years since Randomization









Figure 2. Changes in Blood Pressure, Weight, Waist Circumference, and Mean Plasma Glucose Levels.
Shown are changes over 6 years of follow­up in sitting systolic blood pressure (Panel A), sitting diastolic blood pres­
sure (Panel B), weight (Panel C), waist circumference (Panel D), fasting plasma glucose (Panel E), and plasma glu­
cose measured 2 hours after an oral glucose load (Panel F). To convert the values for glucose to milligrams per deci­
liter, divide by 0.05551. The I bars indicate standard errors.
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Discussion
When added to lifestyle intervention, a single dai-
ly dose of valsartan (up to 160 mg) reduced the 
risk of diabetes but not of cardiovascular events 
in patients with impaired glucose tolerance and 
established cardiovascular disease or risk factors. 
The relative reduction of 14% in the risk of diabe-
tes in the valsartan group would translate into 38 
fewer cases of diabetes per 1000 patients treated 
for 5 years, a reduction that was consistent across 
all subgroups that we examined.
The decline was smaller than that suggested 
by pooled analyses of previous trials of ACE in-
hibitors and ARBs, which suggested a risk reduc-
tion of 25 to 30%.11-15,25 However, these trials 
differed from our study in that not all subjects had 
impaired glucose tolerance, ascertainment and 
other biases may have led to an overestimation 
of the effect of these drugs, and study treatment 
did not include lifestyle modification.26 In addi-
tion, by the end of follow-up in our study, 24% 
of patients in the placebo group were taking an 
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Figure 3. Kaplan–Meier Curves for Three Coprimary Outcomes and Death.
Panel A shows the incidence of diabetes, the coprimary outcome. Panel B shows the coprimary extended cardiovascular outcome, a 
composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, arterial 
revascularization, or hospitalization for unstable angina. Panel C shows the coprimary core cardiovascular outcome, a composite of 
death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Panel D shows the 
outcomes of death from any cause and from cardiovascular (CV) causes. All P values are two­sided. The I bars indicate 95% confidence 
intervals.
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tients in the valsartan group had discontinued 
the study treatment, which probably reduced the 
observed effect of the drug.
Despite these factors, the effect of valsartan 
was greater than that of an ACE inhibitor in the 
only previous trial that had the development of 
diabetes or death as the prospectively defined pri-
mary outcome. In the DREAM study, there was 
a nonsignificant trend toward a reduction in the 
incidence of diabetes in the ramipril group, with 
449 patients who had diabetes in the ramipril 
group, as compared with 489 in the placebo group 
(hazard ratio, 0.91; 95% CI, 0.80 to 1.03; P = 0.15), 
over a median follow-up period of 3 years.16 The 
mechanism by which inhibitors of the renin–
angiotensin system reduce the incidence of dia-
betes is unknown.27-30
Although indirect comparisons can be mislead-
ing, the effect of valsartan was smaller than that 
of lifestyle modification, which reduced the in-
cidence of diabetes by 58% in two trials.5,6 How-
ever, in these two studies, the patient populations 
differed from that in our study, and the study pe-
riods were shorter. In addition, we tested the ef-
fect of valsartan combined with lifestyle modifi-
cation. The effect of valsartan was also smaller 
than that of acarbose, metformin, or rosiglita-
zone, medications that have a recognized glucose-
lowering action, although none of these drugs 
were tested in addition to lifestyle modification or 
for as long as valsartan.
There are several possible reasons that valsar-
tan did not improve cardiovascular outcomes, as 
expected. Our patients differed from those in pre-
vious trials of renin–angiotensin antagonists with 
cardiovascular outcomes in that all the patients 
had impaired glucose tolerance, only a minority 
(24%) had established cardiovascular disease, and 
blood pressure was relatively well controlled. The 
benefit of renin–angiotensin system blockade has 
also been smaller in recent studies than observed 
historically, possibly because of greater use of 
other risk-reducing therapies.14,31-33 The patients 
with cardiovascular disease in our study were ex-
tensively treated with such therapies, including an 
ACE inhibitor in 22% of patients at baseline, and 
the use of nonstudy therapies, including open-
label ACE inhibitors and ARBs, increased during 
follow-up. These factors, coupled with the discon-
tinuation of valsartan in a substantial proportion 
of patients, may have diluted any potential benefit 
of valsartan. Furthermore, lifestyle modification 
improves cardiovascular risk factors34 and, in the 
long term, may also reduce the rate of cardiovas-
cular events.35 Finally, the most convincing evi-
dence of improved cardiovascular outcomes with 
valsartan comes from trials in which patients re-
ceived twice the daily dose that we used.36,37
Although lifestyle modification should remain 
the primary intervention to reduce the risk of dia-
betes in the general population, our findings may 
have implications for the treatment of hyperten-
sion, since the use of both thiazide diuretics and 
beta-blockers has been associated with an in-
creased risk of diabetes.27-29
In conclusion, when added to a lifestyle inter-
vention, valsartan at a daily dose of 160 mg re-
duced the risk of diabetes but did not affect car-
diovascular outcomes in patients with impaired 
glucose tolerance. No safety concerns were iden-
tified.
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